Peter Ian Croucher
Garvan Institute of Medical Research · 361 works · 16,884 citations · h-index 67
Top works
- Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti‐tumour activity
- Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
- The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
- Effect of diet-induced weight loss on total body bone mass
- The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel
- Bisphosphonates: Pharmacology, Mechanisms of Action and Clinical Uses
- The pharmacology of bisphosphonates and new insights into their mechanisms of action
- An atlas of genetic influences on osteoporosis in humans and mice
- Zoledronic Acid Treatment of 5T2MM-Bearing Mice Inhibits the Development of Myeloma Bone Disease: Evidence for Decreased Osteolysis, Tumor Burden and Angiogenesis, and Increased Survival
- Structural mechanisms of trabecular bone loss in man
- Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
- Bone metastases
- Human osteoblasts in culture synthesize collagenase and other matrix metalloproteinases in response to osteotropic hormones and cytokines
- Human myeloma cells shed the interleukin‐6 receptor: inhibition by tissue inhibitor of metalloproteinase‐3 and a hydroxamate‐based metalloproteinase inhibitor
- The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network
- Identification of 153 new loci associated with heel bone mineral density and functional involvement of GPC6 in osteoporosis
- Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
- Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
- A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma
- The dormant cancer cell life cycle